This conditional Ews gene fusion model of tumourigenesis shows that Ews-ERG can cause haematopoietic tumours|the precursor cells are committed cells|This conditional Ews gene fusion model of tumourigenesis|the precursor cells are committed cells|1051..1159|1164..1203|1051..1107|1164..1203|1159166.txt|1160..1163|SS
Epithelial tumours also carry chromosomal translocations|while those in leukaemias, lymphomas, and sarcomas tend to be reciprocal translocations, those in carcinomas are often non-reciprocal translocations [3]|those|while those in leukaemias, lymphomas, and sarcomas tend to be reciprocal translocations, those in carcinomas are often non-reciprocal translocations [3|1472..1528|1534..1686|1540..1545|1534..1685|1159166.txt|1530..1533|SS
those in carcinomas are often non-reciprocal translocations [3]|those in leukaemias, lymphomas, and sarcomas tend to be reciprocal translocations|Epithelial tumours also carry chromosomal translocations|those in leukaemias, lymphomas, and sarcomas tend to be reciprocal translocations|1623..1686|1540..1621|1472..1528|1540..1621|1159166.txt|1534..1539|SS
Gene fusion occurs|the translocation breakpoints are within the introns of genes|Gene fusion|the translocation breakpoints are within the introns of genes, such that the two translocated chromosomes have new exon organisation, leading to the formation of chimaeric mRNA species and, in turn, chimaeric proteins|1874..1892|1898..1959|1874..1885|1898..2115|1159166.txt|1893..1897|SS
Some translocations must function within stem cells to initiate disease|others function in both stem cells and more committed cells to provide related or distinct functions (reviewed in [4])|Some translocations|others function in both stem cells and more committed cells to provide related or distinct functions (reviewed in [4])|2118..2190|2197..2315|2119..2138|2197..2315|1159166.txt|2191..2196|SS
Different tumour phenotypes can result from specific versions of related fusion proteins|the Philadelphia t(9;22) translocation (which yields the BCR-ABL [breakpoint cluster region gene–Abelson leukaemia oncogene] fusion) occurs in both myeloid- and lymphoid-lineage tumours, dictated by the position of the translocation junction within the BCR gene [5]|Different tumour phenotypes can result from specific versions of related fusion proteins|Different tumour phenotypes can result from specific versions of related fusion proteins the Philadelphia t(9;22) translocation (which yields the BCR-ABL [breakpoint cluster region gene–Abelson leukaemia oncogene] fusion) occurs in both myeloid- and lymphoid-lineage tumours, dictated by the position of the translocation junction within the BCR gene [5|2317..2405|2421..2686|2317..2405|2317..2405;2421..2685|1159166.txt|2407..2419|SS
These studies show that the BCR-ABL fusion protein does not confer self-renewal potential on committed myeloid progenitors|other translocation fusion proteins (e.g., MOZ-TIF2) do [7]|These studies|other translocation fusion proteins (e.g., MOZ-TIF2) do [7|2799..2921|2931..2990|2799..2812|2931..2989|1159166.txt|2923..2930|SS
others only function in committed cells such as those translocations mediated by the RAG-VDJ (recombinase activating gene and variable, joining, diversity regions) recombinase of the lymphoid lineage [1]|some translocations have these dual properties|only|some translocations have these dual properties|3447..3650|3399..3445|3454..3458|3399..3445|1159166.txt|3393..3398|SS
A further ramification of this infidelity is that the FUS gene, first identified by its fusion with the CHOP gene in t(12;16) of malignant myxoid liposarcoma and related to the EWS gene [24,25], has also been found in Ewing's sarcoma fused with the ERG gene|also a similar FUS-ERG fusion has been described in some acute myeloid leukaemias [26–28]|been found in Ewing's sarcoma fused with the ERG gene|also a similar FUS-ERG fusion has been described in some acute myeloid leukaemias [26–28|4412..4669|4675..4764|4616..4669|4675..4763|1159166.txt|4671..4674|SS
Thus the EWS fusions function in the cancer precursor cell and are required throughout tumour formation until the emergence of the overt cancer|the chromosomal translocation is present in the cancer at the time of presentation|in the cancer at the time of presentation|the chromosomal translocation is present in the cancer at the time of presentation|5024..5167|5177..5259|5218..5259|5177..5259|1159166.txt|5169..5176|SS
which must be part of the genetic make-up of the cancer stem cell,|the chromosomal translocation is an initiating and persistent feature|an initiating and persistent feature|the chromosomal translocation is an initiating and persistent feature|5397..5463|5470..5539|5503..5539|5470..5539|1159166.txt|5464..5469|SS
clonal T cell lymphoma arose in the invertor model|Cre expression was controlled by the lymphocyte-specific Rag1 gene|clonal T cell lymphoma|Cre expression was controlled by the lymphocyte-specific Rag1 gene|7475..7525|7531..7597|7475..7497|7531..7597|1159166.txt|7526..7530|SS
no clones were obtained with any of the Ews fusions equivalent to those naturally found in human cancers (Table S1)|we were able to obtain homologous recombination knock-in clones either with a vector carrying only a transfer cassette or with the Ews-AF9 control fusion|to obtain homologous recombination knock-in clones either with a vector carrying only a transfer cassette or with the Ews-AF9 control fusion|we were able to obtain homologous recombination knock-in clones either with a vector carrying only a transfer cassette or with the Ews-AF9 control fusion|8379..8494|8224..8377|8237..8377|8224..8377|1159166.txt|8218..8223|SS
In these invertor mice, Ews-ERG protein can only be made after Cre-mediated inversion|and can be cell-specifically dependent on Cre expression|after Cre-mediated inversion|after Cre-mediated inversion and can be cell-specifically dependent on Cre expression|9804..9889|9890..9893;9899..9951|9861..9889|9861..9893;9899..9951|1159166.txt|9894..9898|SS
Out of the cohort of 29 mice carrying both Ews-ERG and Rag1-Cre genes, 25 mice (86%) developed leukaemia associated with thymoma within 500 d|the Ews-ERG-only cohort (20 mice) did not display neoplasia (Figure 2)|with thymoma|the Ews-ERG-only cohort (20 mice) did not display neoplasia (Figure 2)|10151..10292|10302..10372|10267..10279|10302..10372|1159166.txt|10294..10301|SS
The diseased mice all had large thymomas, usually associated with splenomegaly (Table 1) and lymphadenopathy|the histology of spleens showed either complete loss of normal architecture (loss of demarcated white and red pulp), partial loss, or normal architecture (Figure S2)|The diseased mice|the histology of spleens showed either complete loss of normal architecture (loss of demarcated white and red pulp), partial loss, or normal architecture (Figure S2)|10672..10780|10786..10951|10672..10689|10786..10951|1159166.txt|10782..10785|SS
In addition, the steady state orientation of the loxP-flanked ERG cassette was studied using filter hybridisation|we found that the ERG sequence had become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|we found that the ERG sequence had become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|11837..11950|11955..12109|11990..12109|11955..12109|1159166.txt|11951..11954|SS
Studies of progenitor gene expression have indicated the promiscuous expression of lymphoid markers precedes lineage commitment [38]|thus, the Rag1-Cre allele might be expressing in cells destined to become non-lymphoid|Studies of progenitor gene expression|thus, the Rag1-Cre allele might be expressing in cells destined to become non-lymphoid|12490..12622|12627..12713|12490..12527|12627..12713|1159166.txt|12623..12626|SS
the promiscuous expression of lymphoid markers precedes lineage commitment [38]|and the Rag1-Cre allele might be expressing in cells destined to become non-lymphoid|the promiscuous expression of lymphoid markers|the Rag1-Cre allele might be expressing in cells destined to become non-lymphoid|12543..12622|12623..12626;12633..12713|12543..12589|12633..12713|1159166.txt|12627..12631|SS
Haematopoietic populations from mice carrying both Rag1-Cre and ROSA26-R alleles were stained with fluorescent antibodies binding to various surface markers|flow cytometry was carried out for co-detection of antibody- and βgal-derived fluorescence (Figure S3)|Haematopoietic populations from mice carrying both Rag1-Cre and ROSA26-R alleles|flow cytometry was carried out for co-detection of antibody- and βgal-derived fluorescence (Figure S3)|13124..13280|13286..13388|13124..13204|13286..13388|1159166.txt|13282..13285|SS
βgal signal was found in thymus and spleen (almost all cells)|in bone marrow, a population of βgal+ cells exist but did not co-express with CD34, Sca1, Ckit, or Ter119 (or Mac1, not shown)|βgal signal|in bone marrow, a population of βgal+ cells exist but did not co-express with CD34, Sca1, Ckit, or Ter119 (or Mac1, not shown)|13390..13451|13457..13583|13390..13401|13457..13583|1159166.txt|13453..13456|SS
The Rag1-Cre gene is expressed in both B and T cells|only T cell tumours have arisen in the Ews-ERG; Rag1-Cre invertor line|only T cell tumours|only T cell tumours have arisen in the Ews-ERG; Rag1-Cre invertor line|13675..13727|13733..13803|13733..13752|13733..13803|1159166.txt|13729..13732|SS
none showed a CD4+ SP phenotype|we found either CD8+ SP or CD4+CD8+ DP thymomas|either CD8+ SP or CD4+CD8+ DP thymomas|we found either CD8+ SP or CD4+CD8+ DP thymomas|15847..15878|15798..15845|15807..15845|15798..15845|1159166.txt|15792..15797|SS
lymphomas arise|Ews-ERG is aberrantly expressed in the committed cells of the lymphoid lineage|lymphomas|Ews-ERG is aberrantly expressed in the committed cells of the lymphoid lineage|19126..19141|19147..19225|19126..19135|19147..19225|1159166.txt|19142..19146|SS
The T cells were of varying phenotypes|the majority of cases expressed CD8 on the cell surface and had productive V-D-Jβ rearrangements, indicative of mature T cells|were of varying phenotypes|the majority of cases expressed CD8 on the cell surface and had productive V-D-Jβ rearrangements, indicative of mature T cells|19449..19487|19492..19618|19461..19487|19492..19618|1159166.txt|19488..19491|SS
there is potential for the cassette to flip back and forth with continued Cre expression|Cre-mediated inversion through loxP sites recreates the loxP sequence|Cre-mediated inversion|Cre-mediated inversion through loxP sites recreates the loxP sequence|19697..19785|19626..19695|19626..19648|19626..19695|1159166.txt|19620..19625|SS
In some cells, it may be that EWS-FUS fusions are lethal|thus those cells acquiring a translocation would die|it|those cells acquiring a translocation would die|20782..20838|20843..20895|20797..20799|20848..20895|1159166.txt|20839..20842|SS
In some cells, it may be that EWS-FUS fusions are lethal|and those cells acquiring a translocation would die|EWS-FUS fusions|those cells acquiring a translocation would die|20782..20838|20839..20842;20848..20895|20812..20827|20848..20895|1159166.txt|20843..20847|SS
in others, the fusion protein may be tolerated|and may become tumours|in others|In some cells, it may be that EWS-FUS fusions are lethal and thus those cells acquiring a translocation would die; in others, the fusion protein may be tolerated and may become tumours|20897..20943|20944..20947;20953..20971|20897..20906|20782..20947;20953..20971|1159166.txt|20948..20952|SS
In this respect, the absence of B cell tumours in the Ews-ERG invertors is of interest as both B and T cells undergo inversion of the Ews-ERG cassette (see Figure 4)|Rag1-Cre is expressed in both cell types [36] (see Figure S3)|expressed in both cell types [36|Rag1-Cre is expressed in both cell types [36|20973..21138|21147..21208|21159..21191|21147..21191|1159166.txt|21139..21146|SS
The absence of B cell tumours may reflect toxicity of the fusion protein for B cells|this seems unlikely given that we can detect the fusion mRNA in selected B220+ B lymphocytes (see Figure 4)|The absence of B cell tumours|this seems unlikely given that we can detect the fusion mRNA in selected B220+ B lymphocytes (see Figure 4)|21210..21294|21304..21411|21210..21239|21304..21411|1159166.txt|21295..21303|SS
that Ews-ERG does not function in B cells|that the development of B cell tumours is inhibited by the T cell malignancies, which may arise earlier and then dominate the lymphoid compartment|it|that the development of B cell tumours is inhibited by the T cell malignancies, which may arise earlier and then dominate the lymphoid compartment|21440..21481|21485..21631|21428..21430|21485..21631|1159166.txt|21482..21484|SS
The knock-in clones for potential Ews fusions with AF9, Fli1, Chop, and ATF1 were made using a transfer vector pC2A-neo [35]|the sequences of these cDNA cassettes are given in Figure S1|The knock-in clones for potential Ews fusions with AF9, Fli1, Chop, and ATF1|the sequences of these cDNA cassettes are given in Figure S1|22973..23097|23103..23163|22973..23049|23103..23163|1159166.txt|23099..23102|SS
these were injected into C57BL/6 blastocysts, chimaeric mice were produced, and germ line transmission of the inversion knock-in allele was obtained|identification of targeted ES cells|of targeted ES cells|identification of targeted ES cells|23764..23912|23727..23762|23742..23762|23727..23762|1159166.txt|23721..23726|SS
Genomic DNA was prepared from tissues using proteinase K digestion and phenol-chloroform extraction|filter hybridisations were carried out with radiolabelled probes as described [48,49]|Genomic DNA|filter hybridisations were carried out with radiolabelled probes as described [48,49|24146..24245|24251..24336|24146..24157|24251..24335|1159166.txt|24247..24250|SS
T cell receptor V-D-Jβ junction sequences were obtained by PCR amplification from thymoma DNA with pools of Vβ primers and a Jβ2 reverse primer (primer sequences from [42,43])|the product was fractionated on agarose to determine the presence of a single amplified band|T cell receptor V-D-Jβ junction sequences|the product was fractionated on agarose to determine the presence of a single amplified band|24490..24665|24671..24763|24490..24531|24671..24763|1159166.txt|24667..24670|SS
Sequences have been described for Pax5 and CD3 RT-PCR primers [38]|the sequences of the Ews-ERG primers were 5′- CCACAGGATGGTAACAAGCCTGC-3′ (Ews) and 5′- CGAACTTGTAGGCGTAGC-3′ (ERG)|Sequences|the sequences of the Ews-ERG primers were 5′- CCACAGGATGGTAACAAGCCTGC-3′ (Ews) and 5′- CGAACTTGTAGGCGTAGC-3′ (ERG)|25142..25208|25214..25328|25142..25151|25214..25328|1159166.txt|25210..25213|SS
The transcription orientation of the targeted ERG cDNA invertor cassette was opposite from that of the endogenous Ews gene|initial homologous recombination|The transcription orientation of the targeted ERG cDNA invertor cassette|initial homologous recombination|27601..27723|27730..27762|27601..27673|27730..27762|1159166.txt|27724..27729|SS
Germ line carrier mice of this targeted allele were crossed with Cre-expressing mouse strains [36]|as indicated in the right hand side of the diagram, the invertor cassette is turned around to create a transcription orientation identical with that of Ews|Germ line carrier mice of this targeted allele|as indicated in the right hand side of the diagram, the invertor cassette is turned around to create a transcription orientation identical with that of Ews|27764..27862|27869..28024|27764..27810|27869..28024|1159166.txt|27864..27867|SS
a pre-mRNA is made with the donor splice site of Ews exon 7 adjacent to the acceptor site of the invertor cassette|transcription|Thus|transcription|28053..28167|28038..28051|28026..28030|28038..28051|1159166.txt|28032..28037|SS
the size of the EcoRI fragment increases from the initial targeted gene size|the ERG cassette is inverted by Cre activity|inverted by Cre activity|the ERG cassette is inverted by Cre activity|30816..30892|30770..30814|30790..30814|30770..30814|1159166.txt|30767..30769|SS
The hybridisation autoradiograph shows the location of Ews exon 7 and the initial targeted orientation (bottom) or inverted orientation of ERG invertor cassette|Cre-mediated recombination (top). a, acceptor splice site|The hybridisation autoradiograph|Cre-mediated recombination (top)|31634..31794|31801..31858|31634..31666|31801..31833|1159166.txt|31795..31800|SS
that SEB induced the activation of the JNK MAPK pathway in responding T cells in vivo|that ITK null T cells were defective in the activation of this pathway in vivo|We|that ITK null T cells were defective in the activation of this pathway in vivo|4543..4628|4634..4712|4530..4532|4634..4712|1200558.txt|4630..4633|SS
that ITK is required for full IL-2 secretion following SEB exposure|that this may be due to the regulation of the JNK pathway by ITK in vivo|Our data|that this may be due to the regulation of the JNK pathway by ITK in vivo|4843..4910|4916..4988|4826..4834|4916..4988|1200558.txt|4912..4915|SS
Pooled splenocytes and lymph node cells from WT or ITK null animals were cultured in vitro in the presence of varying concentrations of SEB (5 μg/ml, 0.5 μg/ml, 0.05 μg/ml, 0.005 μg/ml, and 0.0005 μg/ml)|proliferation analyzed over a 5-day period|Pooled splenocytes and lymph node cells from WT or ITK null animals|proliferation analyzed over a 5-day period|5749..5952|5958..6000|5749..5816|5958..6000|1200558.txt|5954..5957|SS
ITK null T cells responded less than WT T cells on day 3, 4 and 5 (Fig. 1d–f)|proliferation was equivalent when PMA and Ionomycin was used to bypass TcR signals (data not shown)|less than WT|proliferation was equivalent when PMA and Ionomycin was used to bypass TcR signals (data not shown)|6887..6964|6972..7071|6914..6926|6972..7071|1200558.txt|6966..6971|SS
while proliferation was equivalent|PMA and Ionomycin was used to bypass TcR signals (data not shown)|proliferation|PMA and Ionomycin was used to bypass TcR signals (data not shown)|6966..7000|7006..7071|6972..6985|7006..7071|1200558.txt|7001..7005|SS
ITK null T cells made very little IL-2|the small amount of IL-2 that was made was only at the highest concentration of SEB tested (5 μg/ml)|the small amount of IL-2 that was made|the small amount of IL-2 that was made was only at the highest concentration of SEB tested (5 μg/ml)|7725..7763|7769..7869|7769..7807|7769..7869|1200558.txt|7765..7768|SS
it is possible that within the context of antigen presentation and optimal co-stimulatory signals in vivo, ITK null T cells may exhibit a better response|these data indicate that ITK regulates T cell proliferation in response to SEB in vitro|that ITK regulates T cell proliferation in response to SEB in vitro|these data indicate that ITK regulates T cell proliferation in response to SEB in vitro|8239..8392|8150..8237|8170..8237|8150..8237|1200558.txt|8144..8149|SS
T cells bearing Vβ8 TcR chains are responsive to SEB stimulation|those that bear Vβ6 TcR chains are not|T cells bearing Vβ8 TcR chains|those that bear Vβ6 TcR chains are not|8857..8921|8928..8966|8857..8887|8928..8966|1200558.txt|8922..8927|SS
T cells bearing Vβ8 TcR chains are responsive to SEB stimulation while those that bear Vβ6 TcR chains are not|we analyzed these two populations of T cells|we|we analyzed these two populations of T cells|8857..8966|8971..9015|8971..8973|8971..9015|1200558.txt|8968..8970|SS
an approximately 4 fold expansion in Vβ8 CD4+ T cells in spleen and lymph nodes following SEB exposure (as compared to exposure to PBS, fig 3a,b)|Vβ6 CD4+ T cell populations were largely unchanged (data not shown)|As previously reported|Vβ6 CD4+ T cell populations were largely unchanged (data not shown)|9068..9213|9221..9288|9017..9039|9221..9288|1200558.txt|9215..9220|SS
in comparison to in vitro IL-2 production they produced IL-2 within 1 hr., which peaked at around 2 hrs. (Fig. 4)|WT mice were exposed to SEB in vivo|in vitro IL-2 production|WT mice were exposed to SEB in vivo|10066..10107;10150..10221|10114..10149|10083..10107|10114..10149|1200558.txt|10109..10113|SS
that in vivo IL-2 production occurs earlier than observed in vitro|that ITK null T cells continue to exhibit defects in IL-2 production in response to SEB in vivo, even in the presumed presence of adequate costimulatory signals in vivo|we|that ITK null T cells continue to exhibit defects in IL-2 production in response to SEB in vivo, even in the presumed presence of adequate costimulatory signals in vivo|10398..10464|10470..10638|10386..10388|10470..10638|1200558.txt|10466..10469|SS
it is not clear whether the SAG SEB activates this pathway in vivo [29,30]|activation of the JNK pathway leading to phosphorylation and activation of c-jun has been demonstrated in T cells following TcR and CD28 crosslinking in vitro, as well as by peptide antigen stimulation in vivo|leading to phosphorylation and activation of c-jun|activation of the JNK pathway leading to phosphorylation and activation of c-jun has been demonstrated in T cells following TcR and CD28 crosslinking in vitro, as well as by peptide antigen stimulation in vivo|11145..11219|10934..11143|10964..11014|10934..11143|1200558.txt|10928..10933|SS
In this protocol, mice were exposed to SEB|cells from lymph nodes, spleen and blood rapidly isolated and fixed|In this protocol|In this protocol, mice were exposed to SEB cells from lymph nodes, spleen and blood rapidly isolated and fixed, and antibodies specific for phosphorylated c-jun used to analyze its phosphorylation|11482..11524|11531..11598|11482..11498|11482..11524;11531..11684|1200558.txt|11526..11530|SS
then cells from lymph nodes, spleen and blood rapidly isolated and fixed|antibodies specific for phosphorylated c-jun used to analyze its phosphorylation|antibodies|antibodies specific for phosphorylated c-jun used to analyze its phosphorylation|11526..11598|11604..11684|11604..11614|11604..11684|1200558.txt|11600..11603|SS
This demonstrates that in the same animal, only those T cells that interact with and can be activated by SEB respond by phosphorylation of c-jun|at the same time, those T cells that are not reactive are not activated, demonstrating specificity|This|at the same time, those T cells that are not reactive are not activated, demonstrating specificity|12326..12470|12478..12576|12326..12330|12478..12576|1200558.txt|12472..12477|SS
ITK null mice were exposed to SEB as described above|phosphorylation of c-jun determined in Vβ8+ T cell population (SEB reactive) or Vβ6+ T cell population (non-reactive) in the same animals|ITK null mice|phosphorylation of c-jun determined in Vβ8+ T cell population (SEB reactive) or Vβ6+ T cell population (non-reactive) in the same animals|13024..13076|13082..13219|13024..13037|13082..13219|1200558.txt|13078..13081|SS
its absence does not affect the ability of SEB to induce sickness in these mice|the absence of ITK affects IL-2 secretion following SEB exposure|the absence|the absence of ITK affects IL-2 secretion following SEB exposure|15407..15486|15341..15405|15341..15352|15341..15405|1200558.txt|15332..15340|SS
the SEB induced signaling pathway leading to c-jun phosphorylation, an indication of JNK pathway activation, is significantly reduced in ITK null T cells|these T cells could respond to SEB activation by upregulating CD69|we|these T cells could respond to SEB activation by upregulating CD69|16247..16400|16411..16477|16234..16236|16411..16477|1200558.txt|16402..16410|SS
Furthermore, we show that the SEB induced signaling pathway leading to c-jun phosphorylation, an indication of JNK pathway activation, is significantly reduced in ITK null T cells, although these T cells could respond to SEB activation by upregulating CD69|there was no difference in the overall toxicity of SEB/LPS in these mice compared to WT mice|in ITK null T cells|there was no difference in the overall toxicity of SEB/LPS in these mice compared to WT mice|16221..16477|16483..16575|16381..16400|16483..16575|1200558.txt|16479..16482|SS
However, these experiments were performed in vitro|it is not clear that effects seen in vitro would reflect what happens in vivo|reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|it is not clear that effects seen in vitro would reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|17032..17082|17087..17164|17136..17297|17087..17297|1200558.txt|17083..17086|SS
and it is not clear that effects seen in vitro would reflect what happens in vivo|other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|allow for activation of pathways that are not seen using in vitro activation with antibodies|other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|17083..17164|17172..17297|17205..17297|17172..17297|1200558.txt|17166..17171|SS
Curiously, the immunosuppresant CsA has been shown to inhibit the effects of SEB exposure in mice if delivered prior to SEB exposure [36]|it does not inhibit SEB induced effects in monkeys if delivered at the same time as SEB [38]|Curiously|does not inhibit SEB induced effects in monkeys if delivered at the same time as SEB [38|17844..17981|17991..18083|17844..17853|17994..18082|1200558.txt|17983..17990|SS
The effects of CsA on SEB induced symptoms has been suggested to be due to its effects on inhibiting IL-2 and other cytokine production due to inhibition of activation of the transcription factor NFAT [36,41]|CsA also inhibits activation of the JNK pathway following TcR/CD3 and CD28 stimulation [29,30]|NFAT|NFAT [36,41|18085..18293|18304..18398|18281..18285|18281..18292|1200558.txt|18295..18302|SS
however, CsA also inhibits activation of the JNK pathway following TcR/CD3 and CD28 stimulation [29,30]|and CsA pretreatment may act to prevent early T cell activation of these pathways, thus blocking cytokine production and protecting mice from the effects of subsequent SEB exposure|NFAT|CsA pretreatment may act to prevent early T cell activation of these pathways|18295..18398|18400..18403;18407..18583|18281..18285|18407..18484|1200558.txt|18404..18406|SS
and so CsA pretreatment may act to prevent early T cell activation of these pathways|blocking cytokine production and protecting mice from the effects of subsequent SEB exposure|IL-2 and other cytokine production|inhibiting IL-2 and other cytokine production due to inhibition of activation of the transcription factor NFAT [36,41], however, CsA also inhibits activation of the JNK pathway following TcR/CD3 and CD28 stimulation [29,30], and so CsA pretreatment may act to prevent early T cell activation of these pathways blocking cytokine production and protecting mice from the effects of subsequent SEB exposure|18400..18484|18491..18583|18186..18220|18175..18484;18491..18583|1200558.txt|18486..18490|SS
if these cells were able to respond to SEB, we would expect an equivalent reduction in the amount of IL-2 secreted in vivo in response to SEB|this would be expected to reduced the overall T cell response in vivo to SEB exposure|to reduced the overall T cell response in vivo to SEB exposure|this would be expected to reduced the overall T cell response in vivo to SEB exposure, if these cells were able to respond to SEB|18826..18967|18739..18824|18762..18824|18739..18868|1200558.txt|18733..18738|SS
and reduced expansion of Vβ8+CD4+ T cells|this was not as dramatic as the reduction in IL-2 secretion|However|this was not as dramatic as the reduction in IL-2 secretion|19107..19148|19159..19218|19048..19055|19159..19218|1200558.txt|19150..19158|SS
Thus we observed very few deaths in our experiments|ITK may protect Balb/c mice from actual death|Thus|ITK may protect Balb/c mice from actual death|19677..19728|19734..19779|19677..19681|19734..19779|1200558.txt|19730..19733|SS
that the inability of T cell lacking ITK to produce IL-2 cannot be overcome by SAG stimulation|that perturbing T cell activation pathways leading to IL-2 production does not necessarily lead to improved responses to SEB toxicity|The data|that perturbing T cell activation pathways leading to IL-2 production does not necessarily lead to improved responses to SEB toxicity|20206..20300|20306..20439|20189..20197|20306..20439|1200558.txt|20302..20305|SS
Cells were stained with antibodies to Vβ8 or Vβ6 directly conjugated to PE (BDPharmingen, San Diego, CA)|permeabilized with saponin|Cells|permeabilized with saponin|21979..22083|22090..22116|21979..21984|22090..22116|1200558.txt|22085..22089|SS
Red blood cells were removed using ACK lysis buffer|cells resuspended in complete RPMI|Red blood cells|cells resuspended in complete RPMI|22867..22918|22924..22958|22867..22882|22924..22958|1200558.txt|22920..22923|SS
PBS injected mice served as controls|there was no change in IL-2 secretion in these animals|PBS|there was no change in IL-2 secretion in these animals|24210..24246|24252..24306|24210..24213|24252..24306|1200558.txt|24248..24251|SS
and considered significant|p < 0.05|Values|p < 0.05|24354..24380|24384..24392|24310..24316|24384..24392|1200558.txt|24381..24383|SS
Splenocytes and lymph node cells from WT (filled circles) and ITK deficient (open circles) mice were stimulated in vitro with the indicated concentrations of SEB|proliferative response determined|Splenocytes and lymph node cells from WT (filled circles) and ITK deficient (open circles) mice|proliferative response determined|25446..25607|25613..25646|25446..25541|25613..25646|1200558.txt|25609..25612|SS
The EWS-ERG fusion protein is found in human sarcomas with the chromosomal translocation t(21;22)(q22;q12), where the translocation is considered to be an initiating event in sarcoma formation within uncommitted mesenchymal cells, probably long-lived progenitors capable of self renewal|The fusion protein may not have an oncogenic capability beyond these progenitors|The Ews-ERG Fusion Protein Can Initiate Neoplasia from Lineage-Committed Haematopoietic CellsAbstractThe EWS-ERG fusion protein is found in human sarcomas with the chromosomal translocation t(21;22)(q22;q12), where the translocation is considered to be an initiating event in sarcoma formation within uncommitted mesenchymal cells, probably long-lived progenitors capable of self renewal|The fusion protein may not have an oncogenic capability beyond these progenitors|105..391|393..419;430..483|0..391|393..419;430..483|1159166.txt|420..429|PS
This conditional Ews gene fusion model of tumourigenesis shows that Ews-ERG can cause haematopoietic tumours and the precursor cells are committed cells|Ews-ERG can function in cells that do not have to be pluripotent progenitors or mesenchymal cells|This conditional Ews gene fusion model of tumourigenesis shows that Ews-ERG can cause haematopoietic tumours and the precursor cells are committed cells|Ews-ERG can function in cells that do not have to be pluripotent progenitors or mesenchymal cells|1051..1203|1211..1308|1051..1203|1211..1308|1159166.txt|1205..1209|PS
While some translocations have these dual properties, others only function in committed cells such as those translocations mediated by the RAG-VDJ (recombinase activating gene and variable, joining, diversity regions) recombinase of the lymphoid lineage [1]|naturally occurring translocations, such as that of LMO2(LIM domain only 2) in T cell acute leukaemia, only function in committed cells|While some translocations have these dual properties, others only function in committed cells such as those translocations mediated by the RAG-VDJ (recombinase activating gene and variable, joining, diversity regions) recombinase of the lymphoid lineage [1|naturally occurring translocations, such as that of LMO2(LIM domain only 2) in T cell acute leukaemia, only function in committed cells|3393..3650|3658..3793|3393..3649|3658..3793|1159166.txt|3652..3656|PS
The EWS gene, at Chromosome 22 band q12, was first identified in Ewing's sarcoma by its association with FLI1 and ATF1 [16,17] and subsequently found in subsets of Ewing's sarcoma with either ERG or ETV1, and E1AF and FEV [17–21]|the EWS gene is involved in other sarcomas and with yet different partners, such as WT1 (Wilms tumour 1 gene) in desmoplastic small round cell sarcoma [22] or CHN in myxoid chondrosarcoma [23]|The EWS gene, at Chromosome 22 band q12, was first identified in Ewing's sarcoma by its association with FLI1 and ATF1 [16,17] and subsequently found in subsets of Ewing's sarcoma with either ERG or ETV1, and E1AF and FEV [17–21|the EWS gene is involved in other sarcomas and with yet different partners, such as WT1 (Wilms tumour 1 gene) in desmoplastic small round cell sarcoma [22] or CHN in myxoid chondrosarcoma [23|3974..4203|4218..4410|3974..4202|4218..4409|1159166.txt|4205..4216|PS
A further ramification of this infidelity is that the FUS gene, first identified by its fusion with the CHOP gene in t(12;16) of malignant myxoid liposarcoma and related to the EWS gene [24,25], has also been found in Ewing's sarcoma fused with the ERG gene, but also a similar FUS-ERG fusion has been described in some acute myeloid leukaemias [26–28]|the EWS gene can also be involved with the CHOP gene by chromosomal translocation in malignant myxoid liposarcoma [29], analogous to FUS-CHOP|A further ramification of this infidelity is that the FUS gene, first identified by its fusion with the CHOP gene in t(12;16) of malignant myxoid liposarcoma and related to the EWS gene [24,25], has also been found in Ewing's sarcoma fused with the ERG gene, but also a similar FUS-ERG fusion has been described in some acute myeloid leukaemias [26–28|the EWS gene can also be involved with the CHOP gene by chromosomal translocation in malignant myxoid liposarcoma [29], analogous to FUS-CHOP|4412..4764|4775..4916|4412..4763|4775..4916|1159166.txt|4766..4773|PS
The chromosomal translocations in Ewing's and other sarcomas are considered as primary initiating events|the EWS fusions function in the cancer precursor cell and are required throughout tumour formation until the emergence of the overt cancer, because the chromosomal translocation is present in the cancer at the time of presentation|The chromosomal translocations in Ewing's and other sarcomas are considered as primary initiating events|the EWS fusions function in the cancer precursor cell and are required throughout tumour formation until the emergence of the overt cancer, because the chromosomal translocation is present in the cancer at the time of presentation|4918..5022|5029..5259|4918..5022|5029..5259|1159166.txt|5024..5028|PS
Thus the EWS fusions function in the cancer precursor cell and are required throughout tumour formation until the emergence of the overt cancer, because the chromosomal translocation is present in the cancer at the time of presentation|The fusion protein may be instructive by imparting a phenotype on the cell by affecting a specific differentiation programme, which must be part of the genetic make-up of the cancer stem cell, since the chromosomal translocation is an initiating and persistent feature|Thus the EWS fusions function in the cancer precursor cell and are required throughout tumour formation until the emergence of the overt cancer, because the chromosomal translocation is present in the cancer at the time of presentation|The fusion protein may be instructive by imparting a phenotype on the cell by affecting a specific differentiation programme, which must be part of the genetic make-up of the cancer stem cell, since the chromosomal translocation is an initiating and persistent feature|5024..5259|5261..5283;5294..5539|5024..5259|5261..5283;5294..5539|1159166.txt|5284..5293|PS
While we were able to obtain homologous recombination knock-in clones either with a vector carrying only a transfer cassette or with the Ews-AF9 control fusion, no clones were obtained with any of the Ews fusions equivalent to those naturally found in human cancers (Table S1)|chimaeras could be made with the Ews cassette and the Ews-AF9 knock-in (Table S1)|While we were able to obtain homologous recombination knock-in clones either with a vector carrying only a transfer cassette or with the Ews-AF9 control fusion, no clones were obtained with any of the Ews fusions equivalent to those naturally found in human cancers (Table S1)|chimaeras could be made with the Ews cassette and the Ews-AF9 knock-in (Table S1)|8218..8494|8509..8590|8218..8494|8509..8590|1159166.txt|8496..8507|PS
Blood smears at the time of sacrifice of Ews-ERG; Rag1-Cre mice typically showed elevated numbers of large leukocytes, with lymphoid morphology of different maturities, including lymphoblasts (Figure 2)|bone marrow sections showed high levels of infiltrating lymphoblasts (Figure 2)|Blood smears at the time of sacrifice of Ews-ERG; Rag1-Cre mice typically showed elevated numbers of large leukocytes, with lymphoid morphology of different maturities, including lymphoblasts (Figure 2)|bone marrow sections showed high levels of infiltrating lymphoblasts (Figure 2)|10374..10576|10591..10670|10374..10576|10591..10670|1159166.txt|10578..10589|PS
The diseased mice all had large thymomas, usually associated with splenomegaly (Table 1) and lymphadenopathy, and the histology of spleens showed either complete loss of normal architecture (loss of demarcated white and red pulp), partial loss, or normal architecture (Figure S2)|the level of infiltration of leukaemic lymphocytes into liver and kidney varied, with some having large amounts of perivascular deposits and others marginal levels|The diseased mice all had large thymomas, usually associated with splenomegaly (Table 1) and lymphadenopathy, and the histology of spleens showed either complete loss of normal architecture (loss of demarcated white and red pulp), partial loss, or normal architecture (Figure S2)|the level of infiltration of leukaemic lymphocytes into liver and kidney varied, with some having large amounts of perivascular deposits and others marginal levels|10672..10951|10964..11127|10672..10951|10964..11127|1159166.txt|10953..10962|PS
The presence of Ews-ERG mRNA was confirmed in spleens of these mice, identical with that in Ews-ERG ES cells transfected with Cre expression plasmids (see Figure S1)|the steady state orientation of the loxP-flanked ERG cassette was studied using filter hybridisation and we found that the ERG sequence had become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|The presence of Ews-ERG mRNA was confirmed in spleens of these mice, identical with that in Ews-ERG ES cells transfected with Cre expression plasmids (see Figure S1)|the steady state orientation of the loxP-flanked ERG cassette was studied using filter hybridisation and we found that the ERG sequence had become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|11670..11835|11850..12109|11670..11835|11850..12109|1159166.txt|11837..11848|PS
In addition, the steady state orientation of the loxP-flanked ERG cassette was studied using filter hybridisation and we found that the ERG sequence had become inverted into the 5′ to 3′ orientation with respect to the Ews gene in each case of thymoma (Figure 3A; Table 1)|the presence of the Ews-ERG fusion protein was shown by Western blotting of thymoma proteins using antibodies binding to either Ews or ERG, which detected respectively the normal mouse Ews or Erg proteins and the Ews-ERG fusion molecule in thymoma T cells of an Ews-ERG; Rag1-Cre mouse (Figure 3D)|The other tissues examined have little evidence of an inverted band|the presence of the Ews-ERG fusion protein was shown by Western blotting of thymoma proteins using antibodies binding to either Ews or ERG, which detected respectively the normal mouse Ews or Erg proteins and the Ews-ERG fusion molecule in thymoma T cells of an Ews-ERG; Rag1-Cre mouse (Figure 3D)|11837..12109|12189..12486|12111..12178|12189..12486|1159166.txt|12180..12187|PS
Ews-ERG RT-PCR product was detected in the unfractionated spleen and thymus sources, as well as in the purified, sorted B220+ and Thy1.2+ cells|Cre-mediated inversion of the Ews-ERG gene occurs in both T and B cells|Ews-ERG RT-PCR product was detected in the unfractionated spleen and thymus sources, as well as in the purified, sorted B220+ and Thy1.2+ cells|Cre-mediated inversion of the Ews-ERG gene occurs in both T and B cells|14735..14878|14891..14962|14735..14878|14891..14962|1159166.txt|14880..14889|PS
The clonality of these T cell tumours was assessed by filter hybridisation of genomic thymoma DNA with a T cell receptor β probe (Tcrb) from the Jβ2 region [40] (diagrammatically shown in Figure 3B)|the status of the immunoglobulin locus was examined with a probe from the region between JH and Cμ segments [41] (see Figure 3C)|The Tcrb rearrangement status of the cohort of Ews-ERG leukaemic mice is summarized in Table 1|the status of the immunoglobulin locus was examined with a probe from the region between JH and Cμ segments [41] (see Figure 3C)|16015..16213|16807..16935|16698..16792|16807..16935|1159166.txt|16794..16805|PS
Single Igh allele rearrangements were observed in about half of the cohort (Table 1), including ones in which FACS analysis and Tcrb clonality hybridisations showed the tumours to be clonal T cell malignancies|The Igh rearrangements are likely to be abortive rearrangements|Single Igh allele rearrangements were observed in about half of the cohort (Table 1), including ones in which FACS analysis and Tcrb clonality hybridisations showed the tumours to be clonal T cell malignancies|The Igh rearrangements are likely to be abortive rearrangements|16937..17146|17148..17174;17185..17221|16937..17146|17148..17174;17185..17221|1159166.txt|17175..17184|PS
Human cancers of mesenchymal origin involve the EWS gene with various partner genes, such as in the chromosomal translocation t(21;22)(q22;q12) where EWS fuses with ERG to encode a novel EWS-ERG fusion protein [18]|EWS gene fusions with various partners are described in clear cell sarcoma, desmoplastic small round cell tumours, chondrosarcoma, and myxoid liposarcoma, suggesting that EWS fusion proteins are functional for various cell types of mesenchymal origin and that restrictions in humans are dictated largely by the cells in which the chromosomal translocations occur|DiscussionHuman cancers of mesenchymal origin involve the EWS gene with various partner genes, such as in the chromosomal translocation t(21;22)(q22;q12) where EWS fuses with ERG to encode a novel EWS-ERG fusion protein [18|EWS gene fusions with various partners are described in clear cell sarcoma, desmoplastic small round cell tumours, chondrosarcoma, and myxoid liposarcoma, suggesting that EWS fusion proteins are functional for various cell types of mesenchymal origin and that restrictions in humans are dictated largely by the cells in which the chromosomal translocations occur|17940..18154|18169..18531|17928..18153|18169..18531|1159166.txt|18156..18167|PS
This had no obvious deleterious effect on tumourigenesis in the Ews-ERG invertors as judged by various criteria (tumour penetrance, consistent T cell phenotype, and pathology)|the invertor allele of transformed cells may be fixed in the correct orientation for synthesis of Ews-ERG mRNA when Rag1-Cre is no longer effective|This had no obvious deleterious effect on tumourigenesis in the Ews-ERG invertors as judged by various criteria (tumour penetrance, consistent T cell phenotype, and pathology)|the invertor allele of transformed cells may be fixed in the correct orientation for synthesis of Ews-ERG mRNA when Rag1-Cre is no longer effective|19787..19962|19970..20117|19787..19962|19970..20117|1159166.txt|19964..19968|PS
Thus, the invertor allele of transformed cells may be fixed in the correct orientation for synthesis of Ews-ERG mRNA when Rag1-Cre is no longer effective|the lack of CD4+ SP thymomas is difficult to encompass with this explanation, suggesting that other biological mechanisms may be involved in this bias|Thus, the invertor allele of transformed cells may be fixed in the correct orientation for synthesis of Ews-ERG mRNA when Rag1-Cre is no longer effective|the lack of CD4+ SP thymomas is difficult to encompass with this explanation, suggesting that other biological mechanisms may be involved in this bias|19964..20117|20138..20288|19964..20117|20138..20288|1159166.txt|20119..20136|PS
The Rag1-Cre mouse line used constitutively expresses Cre in lymphoid cells [36], and the resulting Ews-ERG fusion causes T lymphocyte tumours in mice, which is not known in the spectrum of EWS-associated human cancers|FUS-ERG has been found in leukaemias, albeit myeloid type [26,46]|The Rag1-Cre mouse line used constitutively expresses Cre in lymphoid cells [36], and the resulting Ews-ERG fusion causes T lymphocyte tumours in mice, which is not known in the spectrum of EWS-associated human cancers|FUS-ERG has been found in leukaemias, albeit myeloid type [26,46|20292..20510|20531..20596|20292..20510|20531..20595|1159166.txt|20512..20529|PS
The absence of B cell tumours may reflect toxicity of the fusion protein for B cells although this seems unlikely given that we can detect the fusion mRNA in selected B220+ B lymphocytes (see Figure 4)|it may mean that Ews-ERG does not function in B cells or that the development of B cell tumours is inhibited by the T cell malignancies, which may arise earlier and then dominate the lymphoid compartment|The absence of B cell tumours may reflect toxicity of the fusion protein for B cells although this seems unlikely given that we can detect the fusion mRNA in selected B220+ B lymphocytes (see Figure 4)|it may mean that Ews-ERG does not function in B cells or that the development of B cell tumours is inhibited by the T cell malignancies, which may arise earlier and then dominate the lymphoid compartment|21210..21411|21428..21631|21210..21411|21428..21631|1159166.txt|21413..21426|PS
Our results show that the Ews-ERG fusion, normally restricted to sarcomas in humans, can initiate T lymphocyte tumours, if conditionally expressed in committed lymphoid cells|Leukaemogenesis in Ews-ERG invertor mice concurs with the hypothesis that EWS fusions can cause neoplasia arising in various cell types|Our results show that the Ews-ERG fusion, normally restricted to sarcomas in humans, can initiate T lymphocyte tumours, if conditionally expressed in committed lymphoid cells|Leukaemogenesis in Ews-ERG invertor mice concurs with the hypothesis that EWS fusions can cause neoplasia arising in various cell types|21784..21958|21960..22000;22006..22100|21784..21958|21960..22000;22006..22100|1159166.txt|22001..22005|PS
Leukaemogenesis in Ews-ERG invertor mice thus concurs with the hypothesis that EWS fusions can cause neoplasia arising in various cell types|our data imply that the cellular context of EWS-associated chromosomal translocations in humans does not have to be a stem cell or even a multi-potent progenitor, as committed lymphocyte precursors expressing Rag recombinase genes are the leukaemic precursors in our invertor model|Leukaemogenesis in Ews-ERG invertor mice thus concurs with the hypothesis that EWS fusions can cause neoplasia arising in various cell types|our data imply that the cellular context of EWS-associated chromosomal translocations in humans does not have to be a stem cell or even a multi-potent progenitor, as committed lymphocyte precursors expressing Rag recombinase genes are the leukaemic precursors in our invertor model|21960..22100|22111..22392|21960..22100|22111..22392|1159166.txt|22102..22109|PS
Further, our data imply that the cellular context of EWS-associated chromosomal translocations in humans does not have to be a stem cell or even a multi-potent progenitor, as committed lymphocyte precursors expressing Rag recombinase genes are the leukaemic precursors in our invertor model. The same conclusions can be applied to FUS-associated chromosomal translocations that seem to be largely interchangeable with EWS, given the spectrum of cancers in which these are found and the relatedness of FUS- and EWS-coded proteins [24,25]|EWS or FUS chromosomal translocations probably arise more by virtue of accessibility of the genes to chromosomal translocations than by the precise cellular specificity of the resultant fusion proteins|The same conclusions can be applied to FUS-associated chromosomal translocations that seem to be largely interchangeable with EWS, given the spectrum of cancers in which these are found and the relatedness of FUS- and EWS-coded proteins [24,25|EWS or FUS chromosomal translocations probably arise more by virtue of accessibility of the genes to chromosomal translocations than by the precise cellular specificity of the resultant fusion proteins|22102..22638|22646..22847|22394..22637|22646..22847|1159166.txt|22640..22644|PS
T cell receptor V-D-Jβ junction sequences were obtained by PCR amplification from thymoma DNA with pools of Vβ primers and a Jβ2 reverse primer (primer sequences from [42,43]), and the product was fractionated on agarose to determine the presence of a single amplified band|each band was eluted and the sequence obtained using the Jβ2N primer [43] and identified by comparison with the ImMunoGeneTics database [44,45]|T cell receptor V-D-Jβ junction sequences were obtained by PCR amplification from thymoma DNA with pools of Vβ primers and a Jβ2 reverse primer (primer sequences from [42,43]), and the product was fractionated on agarose to determine the presence of a single amplified band|each band was eluted and the sequence obtained using the Jβ2N primer [43] and identified by comparison with the ImMunoGeneTics database [44,45|24490..24763|24774..24917|24490..24763|24774..24916|1159166.txt|24765..24772|PS
Germ line carrier mice of this targeted allele were crossed with Cre-expressing mouse strains [36], and, as indicated in the right hand side of the diagram, the invertor cassette is turned around to create a transcription orientation identical with that of Ews|after transcription, a pre-mRNA is made with the donor splice site of Ews exon 7 adjacent to the acceptor site of the invertor cassette, allowing post-transcriptional fusion of Ews with ERG in an analogous format to that found in human sarcomas with t(21;22)|Germ line carrier mice of this targeted allele were crossed with Cre-expressing mouse strains [36], and, as indicated in the right hand side of the diagram, the invertor cassette is turned around to create a transcription orientation identical with that of Ews|after transcription, a pre-mRNA is made with the donor splice site of Ews exon 7 adjacent to the acceptor site of the invertor cassette, allowing post-transcriptional fusion of Ews with ERG in an analogous format to that found in human sarcomas with t(21;22)|27764..28024|28032..28290|27764..28024|28032..28290|1159166.txt|28026..28030|PS
In vivo analysis of c-jun phosphorylation, previously shown to be critical for regulating IL-2 production, revealed that this pathway was specifically activated in SEB reactive Vβ8+ (but not non-reactive Vβ6+) T cells from WT mice, but not in Vβ8+ T cells from ITK null mice|toxicity analysis indicated that both WT and ITK null animals were similarly affected by SEB exposure|In vivo analysis of c-jun phosphorylation, previously shown to be critical for regulating IL-2 production, revealed that this pathway was specifically activated in SEB reactive Vβ8+ (but not non-reactive Vβ6+) T cells from WT mice, but not in Vβ8+ T cells from ITK null mice|toxicity analysis indicated that both WT and ITK null animals were similarly affected by SEB exposure|1195..1469|1480..1581|1195..1469|1480..1581|1200558.txt|1471..1478|PS
Most SAGs share the ability to simultaneously bind the class II major histocompatibility complex molecules and the variable region of the T cell receptor β-chain, without the need to be processed by antigen presenting cells [1,2]|SEB can interact directly with MHC class II molecules on APCs and activate T cells bearing the proper TcR Vβ chains|Most SAGs share the ability to simultaneously bind the class II major histocompatibility complex molecules and the variable region of the T cell receptor β-chain, without the need to be processed by antigen presenting cells [1,2|SEB can interact directly with MHC class II molecules on APCs and activate T cells bearing the proper TcR Vβ chains|2136..2365|2372..2487|2136..2364|2372..2487|1200558.txt|2367..2371|PS
In vitro, this interaction with the TcR has been shown to lead to the activation of a number of tyrosine kinases, including the Src family kinase Lck, the Syk family kinase Zap-70 and the Tec family kinase ITK (for review see [7-10])|This results in the activation of a number of signaling pathways including members of the MAPK family of kinases, ERK, JNK and p38, followed by transcription factor activation [10]|In vitro, this interaction with the TcR has been shown to lead to the activation of a number of tyrosine kinases, including the Src family kinase Lck, the Syk family kinase Zap-70 and the Tec family kinase ITK (for review see [7-10])|This results in the activation of a number of signaling pathways including members of the MAPK family of kinases, ERK, JNK and p38, followed by transcription factor activation [10|3153..3386|3388..3392;3398..3573|3153..3386|3388..3392;3398..3572|1200558.txt|3393..3397|PS
Mice lacking ITK exhibit reduced proliferation and IL-2 production in vitro, and reduced T cell differentiation in vitro and in vivo, with TH2 cell differentiation preferentially affected [15-19]|these animals are not entirely immunocompromised, with residual responses against LCM, Vaccinia and VS viruses [21]|The observed reduced proliferation of ITK null T cells in vitro is IL-2 dependent as it could be rescued by the addition of exogenous IL-2 [20|these animals are not entirely immunocompromised, with residual responses against LCM, Vaccinia and VS viruses [21|3847..4042|4198..4313|4044..4186|4198..4312|1200558.txt|4189..4196|PS
We show here that mice lacking ITK have much reduced IL-2 production and T cell expansion in response to SEB in vitro and in vivo|We show that SEB induced the activation of the JNK MAPK pathway in responding T cells in vivo, and that ITK null T cells were defective in the activation of this pathway in vivo|We show here that mice lacking ITK have much reduced IL-2 production and T cell expansion in response to SEB in vitro and in vivo|We show that SEB induced the activation of the JNK MAPK pathway in responding T cells in vivo, and that ITK null T cells were defective in the activation of this pathway in vivo|4399..4528|4530..4532;4538..4712|4399..4528|4530..4532;4538..4712|1200558.txt|4533..4537|PS
We also show that SEB induced the activation of the JNK MAPK pathway in responding T cells in vivo, and that ITK null T cells were defective in the activation of this pathway in vivo|toxicity analysis indicated that both WT and ITK null animals were similarly affected by SEB exposure|We also show that SEB induced the activation of the JNK MAPK pathway in responding T cells in vivo, and that ITK null T cells were defective in the activation of this pathway in vivo|toxicity analysis indicated that both WT and ITK null animals were similarly affected by SEB exposure|4530..4712|4723..4824|4530..4712|4723..4824|1200558.txt|4714..4721|PS
and that this may be due to the regulation of the JNK pathway by ITK in vivo|reducing T cell signals does not necessarily lead to better physiological responses to SEB exposure|Our data suggest that ITK is required for full IL-2 secretion following SEB exposure, and that this may be due to the regulation of the JNK pathway by ITK in vivo|reducing T cell signals does not necessarily lead to better physiological responses to SEB exposure|4912..4988|4999..5098|4826..4988|4999..5098|1200558.txt|4990..4997|PS
It has previously been reported that T cells from mice lacking ITK exhibit much reduced proliferation in response to anti-CD3 or TcR antibodies in vitro [15,16,18]|these T cells did not have any defects and actually had higher proliferative responses following anti-CD28/PMA stimulation [20]|ResultsIt has previously been reported that T cells from mice lacking ITK exhibit much reduced proliferation in response to anti-CD3 or TcR antibodies in vitro [15,16,18|these T cells did not have any defects and actually had higher proliferative responses following anti-CD28/PMA stimulation [20|5111..5274|5289..5416|5102..5273|5289..5415|1200558.txt|5276..5287|PS
These data do not provide clear answers as to whether ITK would present a good target for inhibition of SEB induced T cell activation in vivo, and in particular, in the cytokine response observed following SAG exposure|We first tested whether ITK null T cells could respond to SEB stimulation by proliferation in vitro|These data do not provide clear answers as to whether ITK would present a good target for inhibition of SEB induced T cell activation in vivo, and in particular, in the cytokine response observed following SAG exposure|We first tested whether ITK null T cells could respond to SEB stimulation by proliferation in vitro|5418..5636|5638..5640;5651..5747|5418..5636|5638..5640;5651..5747|1200558.txt|5641..5650|PS
We found that WT cells responded normally by proliferating between days 2 and 3, with maximum proliferation observed at day 5 and the 5 μg/ml dose of SEB (Fig. 1a). Analysis of the dose response at 5 days indicated that the WT cells responded in a dose dependent fashion (Fig. 1b)|cells from ITK mice showed very little response, regardless of the dose of SEB used for stimulation (Fig. 1a, b)|Analysis of the dose response at 5 days indicated that the WT cells responded in a dose dependent fashion (Fig. 1b)|cells from ITK mice showed very little response, regardless of the dose of SEB used for stimulation (Fig. 1a, b)|6002..6282|6297..6409|6167..6282|6297..6409|1200558.txt|6284..6295|PS
We therefore first tested whether ITK null T cells could respond to SEB stimulation by proliferation in vitro|We determined if the same results would be obtained in purified T cell populations from these mice|By contrast, cells from ITK mice showed very little response, regardless of the dose of SEB used for stimulation (Fig. 1a, b)|We determined if the same results would be obtained in purified T cell populations from these mice|5638..5747|6411..6413;6419..6514|6284..6409|6411..6413;6419..6514|1200558.txt|6414..6418|PS
Analysis of the data over the 5 days indicated that in the presence of the highest concentration of SEB tested (10 μg/ml), WT T cells responded more robustly than ITK null T cells (see Fig. 1c)|at all the doses tested, our analysis indicated that ITK null T cells responded less than WT T cells on day 3, 4 and 5 (Fig. 1d–f), while proliferation was equivalent when PMA and Ionomycin was used to bypass TcR signals (data not shown)|Analysis of the data over the 5 days indicated that in the presence of the highest concentration of SEB tested (10 μg/ml), WT cells responded more robustly than ITK null T cells (see Fig. 1c)|at all the doses tested, our analysis indicated that ITK null T cells responded less than WT cells on day 3, 4 and 5 (Fig. 1d–f), while proliferation was equivalent when PMA and Ionomycin was used to bypass TcR signals (data not shown)|6631..6824|6834..7071|6631..6756;6759..6824|6834..6926;6929..7071|1200558.txt|6826..6832|PS
Interleukin-2 is one of the cytokines induced by exposure to SEB [22]. ITK has been shown to regulate IL-2 secretion in vitro by T cells stimulated anti-CD3/TcR antibodies or in response to peptide antigen [15,18,23,24]|We determined the levels of IL-2 in supernatants from cells similarly stimulated with SEB in vitro (Fig. 2)|ITK has been shown to regulate IL-2 secretion in vitro by T cells stimulated anti-CD3/TcR antibodies or in response to peptide antigen [15,18,23,24|We determined the levels of IL-2 in supernatants from cells similarly stimulated with SEB in vitro (Fig. 2)|7185..7404|7406..7408;7419..7523|7256..7403|7406..7408;7419..7523|1200558.txt|7409..7418|PS
As previously reported, in WT animals, we observed an approximately 4 fold expansion in Vβ8 CD4+ T cells in spleen and lymph nodes following SEB exposure (as compared to exposure to PBS, fig 3a,b), while Vβ6 CD4+ T cell populations were largely unchanged (data not shown)|there was statistically significantly less expansion of ITK null Vβ8+CD4+ T cells following SEB exposure, although these cells still expanded (Fig. 3a,b)|As previously reported, in WT animals, we observed an approximately 4 fold expansion in Vβ8 CD4+ T cells in spleen and lymph nodes following SEB exposure (as compared to exposure to PBS, fig 3a,b), while Vβ6 CD4+ T cell populations were largely unchanged (data not shown)|there was statistically significantly less expansion of ITK null Vβ8+CD4+ T cells following SEB exposure, although these cells still expanded (Fig. 3a,b) As previously reported, the percentages of T cells bearing Vβ6 did not change over this period in either the WT or ITK null mice (data not shown and [4])|9017..9288|9303..9456|9017..9288|9303..9610|1200558.txt|9290..9301|PS
As previously reported, in WT animals, we observed an approximately 4 fold expansion in Vβ8 CD4+ T cells in spleen and lymph nodes following SEB exposure (as compared to exposure to PBS, fig 3a,b), while Vβ6 CD4+ T cell populations were largely unchanged (data not shown). By contrast, there was statistically significantly less expansion of ITK null Vβ8+CD4+ T cells following SEB exposure, although these cells still expanded (Fig. 3a,b) As previously reported, the percentages of T cells bearing Vβ6 did not change over this period in either the WT or ITK null mice (data not shown and [4])|the absence of ITK results in reduced T cell expansion in vivo in response to SEB|By contrast, there was statistically significantly less expansion of ITK null Vβ8+CD4+ T cells following SEB exposure, although these cells still expanded (Fig. 3a,b) As previously reported, the percentages of T cells bearing Vβ6 did not change over this period in either the WT or ITK null mice (data not shown and [4])|the absence of ITK results in reduced T cell expansion in vivo in response to SEB|9017..9610|9617..9698|9290..9610|9617..9698|1200558.txt|9612..9616|PS
and secrete significantly less IL-2 in vitro in response to SEB|We determined if they would also secrete less IL-2 following SEB stimulation in vivo|T cells from ITK null mice proliferate less in vitro and in vivo, and secrete significantly less IL-2 in vitro in response to SEB|We determined if they would also secrete less IL-2 following SEB stimulation in vivo|9768..9831|9833..9835;9846..9927|9702..9831|9833..9835;9846..9927|1200558.txt|9836..9845|PS
We found that in comparison to in vitro IL-2 production, when WT mice were exposed to SEB in vivo they produced IL-2 within 1 hr., which peaked at around 2 hrs. (Fig. 4)|consistent with the in vitro stimulation, ITK deficient mice secrete significantly less IL-2 in response to SEB in vivo (Fig. 4)|(Fig. 4)|consistent with the in vitro stimulation, ITK deficient mice secrete significantly less IL-2 in response to SEB in vivo (Fig. 4)|10052..10221|10236..10364|10213..10221|10236..10364|1200558.txt|10223..10234|PS
While activation of the JNK pathway leading to phosphorylation and activation of c-jun has been demonstrated in T cells following TcR and CD28 crosslinking in vitro, as well as by peptide antigen stimulation in vivo, it is not clear whether the SAG SEB activates this pathway in vivo [29,30]|We tested whether SEB could induce phosphorylation of c-jun in WT T cells stimulated with SEB in vivo|While activation of the JNK pathway leading to phosphorylation and activation of c-jun has been demonstrated in T cells following TcR and CD28 crosslinking in vitro, as well as by peptide antigen stimulation in vivo, it is not clear whether the SAG SEB activates this pathway in vivo [29,30|We tested whether SEB could induce phosphorylation of c-jun in WT cells stimulated with SEB in vivo|10928..11219|11221..11223;11234..11332|10928..11218|11221..11223;11234..11296;11299..11332|1200558.txt|11224..11233|PS
and antibodies specific for phosphorylated c-jun used to analyze its phosphorylation|cells were stained with antibodies specific to Vβ8 or Vβ6 to detect SEB responsive and non-responsive T cells respectively|In this protocol, mice were exposed to SEB, then cells from lymph nodes, spleen and blood rapidly isolated and fixed, and antibodies specific for phosphorylated c-jun used to analyze its phosphorylation|cells were stained with antibodies specific to Vβ8 or Vβ6 to detect SEB responsive and non-responsive T cells respectively|11600..11684|11699..11821|11482..11684|11699..11821|1200558.txt|11686..11697|PS
Figure 5 demonstrates that 1 hr. after intravenous exposure to SEB, Vβ8+ SEB reactive T cells in spleen and lymph nodes contain higher levels of phosphorylated c-jun (cf. Figs. 5a, b iii & iv). Similar results were found in animals exposed to SEB i.p. (data not shown)|T cells non-reactive to SEB in the same animals, those bearing Vβ6+ TcRs, did not have any increase in phosphorylated c-jun (cf. Figs. 5a, b, i & ii)|Similar results were found in animals exposed to SEB i.p. (data not shown)|T cells non-reactive to SEB in the same animals, those bearing Vβ6+ TcRs, did not have any increase in phosphorylated c-jun (cf. Figs. 5a, b, i & ii)|11892..12160|12175..12324|12086..12160|12175..12324|1200558.txt|12162..12173|PS
These experiments show that in the absence of ITK, SEB does not lead to phosphorylation of c-jun in either T cell population (Fig. 6a–d)|the absence of ITK results in the lack of SEB phosphorylation of c-jun, which could affect the ability of these T cells to produce IL-2|These experiments show that in the absence of ITK, SEB does not lead to phosphorylation of c-jun in either T cell population (Fig. 6a–d)|the absence of ITK results in the lack of SEB phosphorylation of c-jun, which could affect the ability of these T cells to produce IL-2|13221..13357|13365..13500|13221..13357|13365..13500|1200558.txt|13359..13363|PS
Figure 7 demonstrates that Vβ8+CD4+ T cells but not Vβ6+CD4+ T cells from both WT and ITK null mice exhibited increases in CD69 expression 2 hours following SEB exposure, indicating that in both cases, the T cells were responding to SEB activation (Fig. 7)|SEB induced CD69 expression on a higher percentage of Vβ8+CD4+ SEB responding T cells in WT mice than in ITK null mice (73.5 +/- 12% in WT vs. 43.6 +/- 0.5% in ITK null)|Figure 7 demonstrates that Vβ8+CD4+ T cells but not Vβ6+CD4+ T cells from both WT and ITK null mice exhibited increases in CD69 expression 2 hours following SEB exposure, indicating that in both cases, the T cells were responding to SEB activation (Fig. 7)|SEB induced CD69 expression on a higher percentage of Vβ8+CD4+ SEB responding T cells in WT mice than in ITK null mice (73.5 +/- 12% in WT vs. 43.6 +/- 0.5% in ITK null)|14069..14325|14336..14505|14069..14325|14336..14505|1200558.txt|14327..14334|PS
However, SEB induced CD69 expression on a higher percentage of Vβ8+CD4+ SEB responding T cells in WT mice than in ITK null mice (73.5 +/- 12% in WT vs. 43.6 +/- 0.5% in ITK null)|there was no difference in the MFI of CD69 expression WT responding T cells vs. ITK null responding T cells (362.5 _+/- 6.3 in WT vs. 375 +/- 11.3 in ITK null). In addition, there was no difference in the expression of CD25 on WT or ITK null T cells (data not shown)|However, SEB induced CD69 expression on a higher percentage of Vβ8+CD4+ SEB responding T cells in WT mice than in ITK null mice (73.5 +/- 12% in WT vs. 43.6 +/- 0.5% in ITK null)|there was no difference in the MFI of CD69 expression WT responding T cells vs. ITK null responding T cells (362.5 _+/- 6.3 in WT vs. 375 +/- 11.3 in ITK null)|14327..14505|14516..14782|14327..14505|14516..14675|1200558.txt|14507..14514|PS
However, there was no difference in the MFI of CD69 expression WT responding T cells vs. ITK null responding T cells (362.5 _+/- 6.3 in WT vs. 375 +/- 11.3 in ITK null)|there was no difference in the expression of CD25 on WT or ITK null T cells (data not shown)|However, there was no difference in the MFI of CD69 expression WT responding T cells vs. ITK null responding T cells (362.5 _+/- 6.3 in WT vs. 375 +/- 11.3 in ITK null)|there was no difference in the expression of CD25 on WT or ITK null T cells (data not shown)|14507..14675|14690..14782|14507..14675|14690..14782|1200558.txt|14677..14688|PS
Figure 7 demonstrates that Vβ8+CD4+ T cells but not Vβ6+CD4+ T cells from both WT and ITK null mice exhibited increases in CD69 expression 2 hours following SEB exposure, indicating that in both cases, the T cells were responding to SEB activation (Fig. 7). However, SEB induced CD69 expression on a higher percentage of Vβ8+CD4+ SEB responding T cells in WT mice than in ITK null mice (73.5 +/- 12% in WT vs. 43.6 +/- 0.5% in ITK null). However, there was no difference in the MFI of CD69 expression WT responding T cells vs. ITK null responding T cells (362.5 _+/- 6.3 in WT vs. 375 +/- 11.3 in ITK null). In addition, there was no difference in the expression of CD25 on WT or ITK null T cells (data not shown)|the lack of SEB induced c-jun phosphorylation in ITK null T cells seems to reflect the specific role of ITK in regulating this event in response to SEB exposure in vivo|In addition, there was no difference in the expression of CD25 on WT or ITK null T cells (data not shown)|the lack of SEB induced c-jun phosphorylation in ITK null T cells seems to reflect the specific role of ITK in regulating this event in response to SEB exposure in vivo|14069..14782|14789..14957|14677..14782|14789..14957|1200558.txt|14784..14788|PS
Exposure of mice to SEB and LPS results in toxicity culminating in death [1]|We analyzed the effect of exposure to SEB/LPS on ITK null mice|Exposure of mice to SEB and LPS results in toxicity culminating in death [1|We analyzed the effect of exposure to SEB/LPS on ITK null mice|14961..15037|15039..15041;15052..15111|14961..15036|15039..15041;15052..15111|1200558.txt|15042..15051|PS
We therefore analyzed the effect of exposure to SEB/LPS on ITK null mice|in contrast to the results with IL-2 secretion and T cell expansion, both mice were affected similarly (Table 1)|We therefore analyzed the effect of exposure to SEB/LPS on ITK null mice|in contrast to the results with IL-2 secretion and T cell expansion, both mice were affected similarly (Table 1)|15039..15111|15122..15234|15039..15111|15122..15234|1200558.txt|15113..15120|PS
However, in contrast to the results with IL-2 secretion and T cell expansion, both mice were affected similarly (Table 1)|the same proportion of mice became sick following exposure to SEB and LPS, suggesting that although the absence of ITK affects IL-2 secretion following SEB exposure, its absence does not affect the ability of SEB to induce sickness in these mice|However, in contrast to the results with IL-2 secretion and T cell expansion, both mice were affected similarly (Table 1)|the same proportion of mice became sick following exposure to SEB and LPS, suggesting that although the absence of ITK affects IL-2 secretion following SEB exposure, its absence does not affect the ability of SEB to induce sickness in these mice|15113..15234|15241..15486|15113..15234|15241..15486|1200558.txt|15236..15240|PS
Current suggestions for pharmacologically blocking the symptoms of SEB exposure include T cell signal transduction inhibitors such as CsA and Perfenidone|these agents have significant side effects [37,38]|T cells have been shown to be largely responsible for this excessive cytokine production [35,36|Current suggestions for pharmacologically blocking the symptoms of SEB exposure include T cell signal transduction inhibitors such as CsA and Perfenidone these agents have significant side effects [37,38|15766..15919|15930..15980|15668..15763|15766..15919;15930..15979|1200558.txt|15921..15928|PS
We show that mice lacking ITK have significantly reduced T cell expansion and IL-2 secretion upon exposure to SEB in vivo|we show that the SEB induced signaling pathway leading to c-jun phosphorylation, an indication of JNK pathway activation, is significantly reduced in ITK null T cells, although these T cells could respond to SEB activation by upregulating CD69, and there was no difference in the overall toxicity of SEB/LPS in these mice compared to WT mice|We show that mice lacking ITK have significantly reduced T cell expansion and IL-2 secretion upon exposure to SEB in vivo|we show that the SEB induced signaling pathway leading to c-jun phosphorylation, an indication of JNK pathway activation, is significantly reduced in ITK null T cells, although these T cells could respond to SEB activation by upregulating CD69, and there was no difference in the overall toxicity of SEB/LPS in these mice compared to WT mice|16098..16219|16234..16575|16098..16219|16234..16575|1200558.txt|16221..16232|PS
Previous work performed in vitro suggests that ITK is required for the anti-TcR/CD3 antibody mediated activation of the transcription factor NFAT, via regulation of calcium influx into TcR stimulated T cells [19,39]|ITK null T cells exhibit reduced AP-1 DNA binding activity when stimulated in vitro with anti-CD3 antibodies [19]|Previous work performed in vitro suggests that ITK is required for the anti-TcR/CD3 antibody mediated activation of the transcription factor NFAT, via regulation of calcium influx into TcR stimulated T cells [19,39|ITK null T cells exhibit reduced AP-1 DNA binding activity when stimulated in vitro with anti-CD3 antibodies [19|16579..16794|16796..16812;16818..16914|16579..16793|16796..16812;16818..16913|1200558.txt|16813..16817|PS
ITK null T cells also exhibit reduced AP-1 DNA binding activity when stimulated in vitro with anti-CD3 antibodies [19]|It has been shown that JNK activation lies in part downstream of ITK following TcR crosslinking in vitro [23]|ITK null T cells also exhibit reduced AP-1 DNA binding activity when stimulated in vitro with anti-CD3 antibodies [19|It has been shown that JNK activation lies in part downstream of ITK following TcR crosslinking in vitro [23|16796..16914|16916..16922;16928..17030|16796..16913|16916..16922;16928..17029|1200558.txt|16923..16927|PS
Previous work performed in vitro suggests that ITK is required for the anti-TcR/CD3 antibody mediated activation of the transcription factor NFAT, via regulation of calcium influx into TcR stimulated T cells [19,39]. ITK null T cells also exhibit reduced AP-1 DNA binding activity when stimulated in vitro with anti-CD3 antibodies [19]. It has also been shown that JNK activation lies in part downstream of ITK following TcR crosslinking in vitro [23]|these experiments were performed in vitro and it is not clear that effects seen in vitro would reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|It has also been shown that JNK activation lies in part downstream of ITK following TcR crosslinking in vitro [23|these experiments were performed in vitro and it is not clear that effects seen in vitro would reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|16579..17030|17041..17297|16916..17029|17041..17297|1200558.txt|17032..17039|PS
However, these experiments were performed in vitro and it is not clear that effects seen in vitro would reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|Our data suggest that indeed, ITK lies downstream of the TcR and is required for IL-2 secretion and c-jun phosphorylation in vivo|However, these experiments were performed in vitro and it is not clear that effects seen in vitro would reflect what happens in vivo, since other cell-cell interactions may allow for activation of pathways that are not seen using in vitro activation with antibodies|Our data suggest that indeed, ITK lies downstream of the TcR and is required for IL-2 secretion and c-jun phosphorylation in vivo|17032..17297|17299..17307;17317..17437|17032..17297|17299..17307;17317..17437|1200558.txt|17308..17315|PS
we would expect an equivalent reduction in the amount of IL-2 secreted in vivo in response to SEB|We would expect to see an equivalent reduction in proliferation in vitro|While this would be expected to reduced the overall T cell response in vivo to SEB exposure, if these cells were able to respond to SEB, we would expect an equivalent reduction in the amount of IL-2 secreted in vivo in response to SEB|We would expect to see an equivalent reduction in proliferation in vitro|18870..18967|18969..18977;18983..19046|18733..18967|18969..18977;18983..19046|1200558.txt|18978..18982|PS
While this would be expected to reduced the overall T cell response in vivo to SEB exposure, if these cells were able to respond to SEB, we would expect an equivalent reduction in the amount of IL-2 secreted in vivo in response to SEB. We would also expect to see an equivalent reduction in proliferation in vitro|in vivo, we observed much reduced IL-2 secretion, and reduced expansion of Vβ8+CD4+ T cells|We would also expect to see an equivalent reduction in proliferation in vitro|in vivo, we observed much reduced IL-2 secretion, and reduced expansion of Vβ8+CD4+ T cells, although this was not as dramatic as the reduction in IL-2 secretion|18733..19046|19057..19148|18969..19046|19057..19218|1200558.txt|19048..19055|PS
However, in vivo, we observed much reduced IL-2 secretion, and reduced expansion of Vβ8+CD4+ T cells, although this was not as dramatic as the reduction in IL-2 secretion|it has been observed that SEB induced T cell expansion in IL-2 null mice, indicating that IL-2 is not necessary for expansion of T cells in vivo following SEB exposure|However, in vivo, we observed much reduced IL-2 secretion, and reduced expansion of Vβ8+CD4+ T cells, although this was not as dramatic as the reduction in IL-2 secretion|it has been observed that SEB induced T cell expansion in IL-2 null mice, indicating that IL-2 is not necessary for expansion of T cells in vivo following SEB exposure|19048..19218|19228..19395|19048..19218|19228..19395|1200558.txt|19220..19226|PS
However, in vivo, we observed much reduced IL-2 secretion, and reduced expansion of Vβ8+CD4+ T cells, although this was not as dramatic as the reduction in IL-2 secretion|even with the reduced T cell responses observed in ITK null mice, they still suffer from SEB/LPS induced toxicity similar to that seen in the WT mice|Indeed, it has been observed that SEB induced T cell expansion in IL-2 null mice, indicating that IL-2 is not necessary for expansion of T cells in vivo following SEB exposure|even with the reduced T cell responses observed in ITK null mice, they still suffer from SEB/LPS induced toxicity similar to that seen in the WT mice|19048..19218|19406..19555|19220..19395|19406..19555|1200558.txt|19397..19404|PS
However, even with the reduced T cell responses observed in ITK null mice, they still suffer from SEB/LPS induced toxicity similar to that seen in the WT mice|It should be noted that C57BL/6 mice are much less sensitive to SEB induce lethal shock than Balb/c mice [34]|However, even with the reduced T cell responses observed in ITK null mice, they still suffer from SEB/LPS induced toxicity similar to that seen in the WT mice|It should be noted that C57BL/6 mice are much less sensitive to SEB induce lethal shock than Balb/c mice [34|19397..19555|19557..19575;19585..19675|19397..19555|19557..19575;19585..19674|1200558.txt|19576..19583|PS
It should be noted however, that C57BL/6 mice are much less sensitive to SEB induce lethal shock than Balb/c mice [34]|we observed very few deaths in our experiments|It should be noted however, that C57BL/6 mice are much less sensitive to SEB induce lethal shock than Balb/c mice [34|we observed very few deaths in our experiments, and ITK may protect Balb/c mice from actual death|19557..19675|19682..19728|19557..19674|19682..19779|1200558.txt|19677..19681|PS
In conclusion, we have show that ITK is required for IL-2 production induced by SEB in vivo and in vitro|We have shown that ITK may regulate signals leading IL-2 production in part by regulating phosphorylation of c-jun|ConclusionIn conclusion, we have show that ITK is required for IL-2 production induced by SEB in vivo and in vitro|We have shown that ITK may regulate signals leading IL-2 production in part by regulating phosphorylation of c-jun|19893..19997|19999..20006;20012..20118|19881..19997|19999..20006;20012..20118|1200558.txt|20007..20011|PS
We have also shown that ITK may regulate signals leading IL-2 production in part by regulating phosphorylation of c-jun|mice lacking ITK exhibit similar responses to SEB toxicity|We have also shown that ITK may regulate signals leading IL-2 production in part by regulating phosphorylation of c-jun|mice lacking ITK exhibit similar responses to SEB toxicity|19999..20118|20129..20187|19999..20118|20129..20187|1200558.txt|20120..20127|PS
WT and ITK deficient mice were injected intraperitoneally (i.p.) with 50 μg SEB in PBS (Sigma-Aldrich, St. Louis, MO) and after 2 days, were sacrificed and splenocytes stained with antibodies specific for Vβ8 (SEB reactive T cells) or Vβ6 (non-reactive T cells) and CD4 directly conjugated to FITC and PE respectively (BDPharmingen, San Diego, CA)|mice were injected i.p. with 50 μg SEB and eye-bled every 2 days for 5 days|WT and ITK deficient mice were injected intraperitoneally (i.p.) with 50 μg SEB in PBS (Sigma-Aldrich, St. Louis, MO) and after 2 days, were sacrificed and splenocytes stained with antibodies specific for Vβ8 (SEB reactive T cells) or Vβ6 (non-reactive T cells) and CD4 directly conjugated to FITC and PE respectively (BDPharmingen, San Diego, CA)|mice were injected i.p. with 50 μg SEB and eye-bled every 2 days for 5 days|20808..21155|21172..21247|20808..21155|21172..21247|1200558.txt|21157..21170|PS
then permeabilized with saponin|Cells were stained for intracellular phosphorylated-c-jun with a monoclonal antibody against phosphorylated c-jun (IgG1, Cell Signaling, Beverly, MA)|Cells were stained with antibodies to Vβ8 or Vβ6 directly conjugated to PE (BDPharmingen, San Diego, CA), then permeabilized with saponin|Cells were stained for intracellular phosphorylated-c-jun with a monoclonal antibody against phosphorylated c-jun (IgG1, Cell Signaling, Beverly, MA), followed by biotinylated rabbit anti-mouse IgG1 and streptavidin conjugated to FITC|22085..22116|22118..22128;22134..22272|21979..22116|22118..22128;22134..22357|1200558.txt|22129..22133|PS
Red blood cells were removed using ACK lysis buffer, and cells resuspended in complete RPMI|Cells were left unstimulated or stimulated with varying concentrations of SEB (5 μg/ml, 0.5 μg/ml, 0.05 μg/ml, 0.005 μg/ml, and 0.0005 μg/ml) at a concentration of 2 × 106 cells/ml|Red blood cells were removed using ACK lysis buffer, and cells resuspended in complete RPMI|Cells were left unstimulated or stimulated with varying concentrations of SEB (5 μg/ml, 0.5 μg/ml, 0.05 μg/ml, 0.005 μg/ml, and 0.0005 μg/ml) at a concentration of 2 × 106 cells/ml|22867..22958|22960..22970;22976..23145|22867..22958|22960..22970;22976..23145|1200558.txt|22971..22975|PS
WT (top panels) or ITK null (bottom panels) mice were injected with 50 μg SEB or PBS i.v. and sacrificed after 1 hr|Splenocytes were analyzed for the presence of phosphorylated c-jun in the Vβ8+ and Vβ6+ T cell populations|WT (top panels) or ITK null (bottom panels) mice were injected with 50 μg SEB or PBS i.v. and sacrificed after 1 hr|Splenocytes were analyzed for the presence of phosphorylated c-jun in the Vβ8+ and Vβ6+ T cell populations|28674..28789|28791..28807;28813..28902|28674..28789|28791..28807;28813..28902|1200558.txt|28808..28812|PS
WT (top panels) or ITK null (bottom panels) mice were injected with 50 μg SEB or PBS i.v. and sacrificed after 2 hrs|Splenocytes were analyzed for the presence of CD69 on the Vβ8+ and Vβ6+ T cell populations|WT (top panels) or ITK null (bottom panels) mice were injected with 50 μg SEB or PBS i.v. and sacrificed after 2 hrs|Splenocytes were analyzed for the presence of CD69 on the Vβ8+ and Vβ6+ T cell populations|29135..29251|29253..29269;29275..29348|29135..29251|29253..29269;29275..29348|1200558.txt|29270..29274|PS
Mice (WT or ITK null) were injected with the indicated amount of LPS, followed 4 hours later by 50 μg SEB, both delivered Ip|mice were injected with 20 mg. D-Gal and 50 μg SEB at the same time|Mice (WT or ITK null) were injected with the indicated amount of LPS, followed 4 hours later by 50 μg SEB, both delivered Ip|mice were injected with 20 mg|29554..29678|29695..29762|29554..29678|29695..29724|1200558.txt|29680..29693|PS
Mice (WT or ITK null) were injected with the indicated amount of LPS, followed 4 hours later by 50 μg SEB, both delivered Ip. Alternatively, mice were injected with 20 mg. D-Gal and 50 μg SEB at the same time|Mice were monitored for the presence of ruffled fur, mucous in feces and lethargy|All injections were delivered intraperitoneally|Mice were monitored for the presence of ruffled fur, mucous in feces and lethargy|29554..29762|29813..29822;29828..29899|29764..29811|29813..29822;29828..29899|1200558.txt|29823..29827|PS
